ESR1 and breast cancer: Moreover, it displayed enhanced inhibitory activity against estrogen receptor positive (ER+) MCF7 and estrogen receptor negative (ER-) MDA-MB231 breast cancer cell growth and had a higher bioavailability of 23% compared to RSV.